T he importance of abnormal renal sodium handling in the pathogenesis of hypertension and salt sensitivity has stimulated studies on the interaction between counterregulatory natriuretic pathways. Dopamine and angiotensin II stimulate 2 counterregulatory pathways through specific G protein-coupled receptors in the renal proximal tubule where the natriuretic effect of the dopamine type 1 (D 1 R) and dopamine type 5 receptors (D 5 R) 1-6 and the antinatriuretic effect of the angiotensin type 1 receptor (AT 1 R) 7 counterbalance each other to maintain sodium and blood pressure homeostasis.
T he importance of abnormal renal sodium handling in the pathogenesis of hypertension and salt sensitivity has stimulated studies on the interaction between counterregulatory natriuretic pathways. Dopamine and angiotensin II stimulate 2 counterregulatory pathways through specific G protein-coupled receptors in the renal proximal tubule where the natriuretic effect of the dopamine type 1 (D 1 R) and dopamine type 5 receptors (D 5 R) [1] [2] [3] [4] [5] [6] and the antinatriuretic effect of the angiotensin type 1 receptor (AT 1 R) 7 counterbalance each other to maintain sodium and blood pressure homeostasis.
The renal proximal tubule and thick-ascending limb of Henle are the sites of increased sodium reabsorption in human essential hypertension, 8 -10 which is regulated by dopamine 1-5,9 -12 and angiotensin II. 7, 9, 10, 13 Angiotensin II is responsible for Ͼ50% of sodium reabsorbed by the kidney under basal conditions, 7, 13, 14 whereas dopamine is responsible for Ͼ50% of sodium excreted under conditions of sodium excess. [1] [2] [3] [4] [5] 12, 15 Previous studies in normotensive rodents demonstrated that stimulation of both the D 1 R and D 5 R by D 1 -like receptor agonists (because of the lack of availability of pharmacological agents that are selective only to the D 1 R or the D 5 R) decreased AT 1 R protein expression but increased the expression of the D 1 R. 16 In the spontaneously hypertensive rat, a rodent model of genetic hypertension and D 1 R and D 5 R stimulation also decreased AT 1 R, but not the D 1 R protein, in renal proximal tubular cells (RPTCs). 16 Whether the D 1 R and/or the D 5 R regulate the AT 1 R in human RPTCs or the spontaneously hypertensive rat has not been directly determined.
The natriuretic effect of D 1 -like receptor stimulation is enhanced when the biosynthesis of angiotensin II is reduced or when the AT 1 R is blocked, 17, 18 suggesting that angiotensin II exerts a tonic control of the dopaminergic pathway. D 1 R can regulate AT 1 R function by direct receptor/receptor interaction, 16, 19 but a regulatory role of D 5 R on AT 1 R has not been demonstrated directly. The enhanced antinatriuretic effect of the renin-angiotensin system in genetic hypertension could be further exacerbated by the impaired counteractive natriuretic effect of the renal dopaminergic system. 15 The mechanisms responsible for the counterregulation of the dopaminergic and AT 1 Rs under normal blood pressure conditions are not well understood.
Despite the fact that the D 1 R and D 5 R arise from different genes and exhibit 49% amino acid sequence homology, they have similar affinities toward dopaminergic agonists and antagonists. 20 -22 Therefore, to test our hypothesis that there is differential regulation of the AT 1 R by the D 1 R and D 5 R, we selectively silenced the D 1 R or D 5 R gene using antisense oligonucleotides selective to either D 1 R or D 5 R. In addition, we used human RPTC lines in which the D 1 Rs are uncoupled from intracellular signaling (D 1 R-uncoupled RPTC) 23, 24 to determine the selective D 5 R (in the absence of a functional D 1 R) effect on AT 1 R expression in these cells.
Materials and Methods

Human RPTC Cultures
Human kidneys were obtained as fresh surgical specimens from patients who had unilateral nephrectomy because of renal carcinoma or trauma under a university institutional review board-approved protocol that included informed consent that adheres to the Declaration of Helsinki and the most recent version of Title 45, Part 46, US Code of Federal Regulations. Only the visually and histologically normal pole, distal from the affected part of the kidney, was used in our studies. All of the studies were performed in duplicate on 3 established lines of RPTCs. We have reported previously on the characteristics of these cell lines, including cell lines from hypertensive subjects with D 1 Rs that are uncoupled from G proteins and other effector proteins. [23] [24] [25] RPTCs were grown at 37°C, 100% humidity, 95% air, and 5% CO 2 and fed serum-free medium every 4 days consisting of a mixture of Click's RPMI 1640 (Quality Biological Inc) supplemented with 5 g/mL of insulin, 5 g/mL of transferrin, 5 ng/mL of selenium, 36 ng/mL of hydrocortisone, 4 pg/mL of triiodothyronine, 10 ng/mL of epidermal growth factor (Sigma), 100 U/mL of penicillin G, and 100 g/mL of streptomycin. [23] [24] [25] Before reaching confluence, the cells were subcultured using trypsin-EDTA (0.025%; 0.01%), inactivating the trypsin with 5% serum, spun at 60g, and resuspended in serum-free growth medium for passaging. Cells were used at 70% to 80% confluence in 6-well culture plates between the first and fourth doublings, with experiments performed in duplicate in 3 cell lines. 26 Clasto-lactacystin ␤-lactone (CLBL), a highly specific cell-permeable proteasome inhibitor, was used at the 10 mol/L concentration. 27 
Drug Treatment
Immunoblotting
Cells were homogenized in ice-cold lysis buffer (20 mmol/L of Tris-HCl [pH 7.4], 2 mmol/L of EDTA [pH 8.0], 2 mmol/L of EGTA, 100 mmol/L of NaCl, 10 g/mL of leupeptin, 10 g/mL of aprotinin, 2 mmol/L of phenylmethylsulfonyl fluoride, and 1% Nonidet P-40), sonicated, kept on ice for 1 hour, and centrifuged at 26 000g for 30 minutes. The supernatant represented crude cell membranes. Protein concentrations were determined by the BCA protein assay kit (Pierce Biotechnology), using BSA as a standard. The proteins, separated by SDS-polyacrylamide gel electrophoresis, were electrophoretically transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories). Equal sample loading and transfer were determined by Ponceau S (Sigma) staining of the polyvinylidene fluoride membrane before immunodetection. Transblots were blocked with 5% nonfat dry milk in Dulbecco's PBS with 0.05% Tween-20 and incubated with diluted affinity-purified rabbit polyclonal antibody to AT 1 R (1:400 dilution, sc-1173, Santa Cruz), D 1 R (1:200 dilution, sc-14001, Santa Cruz), D 5 R (1:500 dilution, sc-25650, Santa Cruz), phosphoextracellular signal-regulated kinase (ERK) 1 and 2, c-Src, and phosphor tyrosine Y416 c-Src (1:1000, Cell Signaling Inc) for 1.5 hours at room temperature. After 5 washes for 10 minutes each, the membranes were incubated with diluted peroxidase-labeled goat anti-rabbit IgG (Santa Cruz Biotechnology Inc) in 2% milk for 1.5 hours at room temperature and washed as for the primary antibody. The chemiluminescence signal was developed using SuperSignal West Pico substrate (Pierce Biotechnology) for AT 1 R and phospho-ERK 1 and 2; SuperSignal West Femto (Pierce Biotechnology) for D 1 R and D 5 R; and c-Src and was then exposed to x-ray film.
Cell Plasma Membrane Expression of AT 1 R
Cell-surface membrane sheets were isolated with a detergent-free isolation procedure using sulfo-NHS-SS-biotin. 28 RPTCs, after a 20-minute incubation with the D 1 -like receptor agonist fenoldopam (10 Ϫ6 mol/L), were washed twice with Hank's balanced salt solution with magnesium and calcium and then labeled with 1 mmol/L of sulfo-NHS-SS-biotin for 10 minutes. The labeling compound was simultaneously washed and inactivated with 2 washes of Trisbuffered saline. The cells were then scraped off the plate in ice-cold detergent-free lysis buffer (Tris-buffered saline with protease inhibitors), sonicated for 1 second, incubated on ice with streptavidin beads (Ultralink, Pierce) for 20 minutes, washed twice with Trisbuffered saline, and eluted in gel loading buffer (NuPAGE LDS Sample Preparation Buffer with reducing agents, Invitrogen). Immunoblotting for AT 1 R protein was performed as described above.
Antisense Oligonucleotides
The effects of 50 nM of propyne/phosphorothioate-modified antisense oligonucleotides for human (h)D 5 R (5Ј-136 nucleotide CAG-CATTTCGGGCTGGAC 153 nucleotide -3Ј; GenBank accession No. M67439) and hD 1 R (5Ј-277 nucleotide GGTGTTCAGAGTC-CTCAT 294 nucleotide-3Ј; GenBank accession No. X55760) were compared with scrambled sequence controls (hD 5 5Ј-GTCGCCCGAGCTTATGGA-3Ј and hD 1 R 5Ј-GGGTACTCTCT ATATCGG-3Ј). Briefly, cells were grown in 6-well plates until 60% confluence, and 50 nM antisense or scrambled oligonucleotides were mixed with 6 L of oligofectamine in Optimem medium (Invitrogen Life Technologies) and incubated for 24 hours, then switched to growth medium and incubated for an another 24 hours. Fenoldopam (10 Ϫ6 mol/L) was then added to the medium without growth factors for 2 hours, lysed, and processed for immunoblotting for the D 1 R, D 5 R, and AT 1 R.
Statistical Analysis
The data are expressed as meanϮSE. Comparisons within and among groups were made by repeated-measures or factorial ANOVA, respectively, followed by Holm-Sidak or Duncan's test. A t test was used for 2-group comparisons. A P value of Ͻ0.05 was considered significant. blocked the fenoldopam-dependent decrease in AT 1 R expression by 57.9Ϯ13.6% (nϭ3; PϽ0.001; Figure 4C ). These studies suggest that D 5 R but not D 1 R mediates the inhibitory effect of fenoldopam on AT 1 R protein expression. The increase in AT 1 R protein in cells not exposed to fenoldopam but treated with D 5 R antisense oligonucleotides supports the notion that D 5 R is constitutively active. 32 Because the fenoldopam-mediated decrease in AT 1 R expression occurred too fast to be accounted for by alterations in transcription and translation (half-life: 0.47Ϯ0.18 hours), we determined whether the action may have occurred by enhancement of its degradation. In HEK-293 cells heterologously expressing the AT 1 R and D 5 R, pulse chase experiments with protein translation inhibited by cycloheximide showed that fenoldopam promoted AT 1 R degradation via the proteasome. 33 Because protein degradation in the proteasome can be triggered by c-Src tyrosine kinase, 26 we studied the effect of fenoldopam (10 Ϫ6 mol/L) on AT 1 R expression in cells treated with PP2, a c-Src nonreceptor tyrosine kinase inhibitor, or CLBL (a proteasome inhibitor). 27 As shown in Figure 5 , either PP2 or CLBL completely blocked the fenoldopam (10 Ϫ6 mol/L for 4 hours)-mediated decrease in AT 1 R expression. We selected concentrations of PP2 and CLBL that, by themselves, had no significant effect on AT 1 R expression; high concentrations of PP2 and CLBL by themselves caused an increase in AT 1 R expression (data not shown). Presumably, the effect of fenoldopam was exerted via c-Src, because fenoldopam increased c-Src tyrosine phosphorylation at the Y416 site by 2.7Ϯ0.4-fold over the control group (vehicle-treated cells), and this increase was completely blocked by the c-Src tyrosine kinase inhibitor PP2 ( Figure 6 ). 
Results
Studies in RPTCs
Studies in RPTCs With
Studies in Surface Labeling of AT 1 R
AT 1 R was reduced in our whole-cell preparations. However, we wished to determine whether cell surface expression was reduced, because cell surface receptors are most likely be the 
Discussion
The current study in human RPTCs confirms our previous studies in rodent RPTCs where we demonstrated that simultaneous D 1 R and D 5 R stimulation results in a decrease in the expression of the AT 1 R protein. 16 The current studies extend these earlier findings by demonstrating in human RPTCs that the D 5 R is responsible for AT 1 R downregulation. We conducted our studies in 6 human RPTC lines, 3 derived from normal subjects (with no significant medical history of hypertension) and 3 that have demonstrated a coupling defect between the D 1 R and adenylyl cyclase activity, termed "D 1 R uncoupled RPTCs," [23] [24] [25] similar to those noted in RPTCs from spontaneously hypertensive rats. 34 The D 1 -like receptor is natriuretic, [1] [2] [3] [4] [5] 12, 15 whereas the AT 1 R is antinatriuretic 7, 13, 14, 35 ; thus, a downregulation of AT 1 R expression and function by the D 1 R and/or D 5 R should amplify the natriuretic effect of D 1 -like receptor stimulation. Indeed, in normotensive rats and dogs, the natriuretic effect of the D 1 -like agonist fenoldopam is enhanced in the presence of inhibition of angiotensin II synthesis or AT 1 R blockade. 17, 18 There is impairment of the ability of the D 1 -like receptor agonist fenoldopam to inhibit renal proximal tubule sodium transport in humans with salt-sensitive essential hypertension or to induce a natriuresis in rodent models of essential hypertension. 1-5,23,36 -38 The relative contributions of D 1 R and D 5 R to the sodium retention in human essential hypertension and rodent models of genetic hypertension remain to be tested.
The ability of D 5 R to decrease AT 1 R expression in vitro may have a physiological consequence in vivo. D 5 R-deficient mice are hypertensive because of renal and nonrenal mechanisms. The acute regulation of the high blood pressure in D 5 R-deficient mice seems to be mediated by a central nervous system mechanism involving the ␣ 1 -adrenergic pathway. 39 However, chronic administration of the AT 1 R antagonist losartan decreases blood pressure to a greater extent in D 5 R-deficient mice than their wild-type littermates (Dr Pedro A. Jose, unpublished data, 2007) . Although the D 5 R action (inhibition of AT 1 R expression) persists in RPTCs from genetically hypertensive rodents, renal D 5 R expression is decreased. 40 Therefore, the impaired D 1 -like receptor inhibition of sodium transport in hypertension may be secondary to impairment of both D 1 R and D 5 R (function and/or expression), at least in rodents. Indeed, disruption of either the D 1 R or D 5 R gene in mice results in hypertension. 39, 41 The D 5 R-mediated AT 1 R downregulation occurs in 30 minutes, too fast for transcriptional-based protein downregulation of AT 1 R protein expression in the human renal proximal tubule (Dr Pedro A. Jose, unpublished data, 2007). In HEK-293 cells heterologously expressing the AT 1 R and D 5 R but not D 1 R, pulse chase experiments, with protein translation inhibited by cycloheximide, show that fenoldopam also decreases AT 1 R expression with a half-life of 37.7 minutes, close 33 to the half-life of 28.2 minutes observed in the current report. The process must be related to increased degradation, because the D 5 R-mediated reduction of AT 1 R is completely blocked by an inhibitor of proteasome activity. There are examples of protein-linked proteasome-and c-Src tyrosine kinase-mediated protein degradation, 26 suggesting that a similar pathway may be active in AT 1 R downregulation. In fact, we demonstrate that fenoldopam mediates the decrease in total cell AT 1 R expression as a result of a c-Src-and proteasome-dependent process. c-Src, when tyrosine phosphorylated at Y416 in the activation loop of the enzyme, increases enzymatic activity. 42 It has been shown previously that the protein kinase A-dependent phosphorylation of c-Src at serine 17 is followed by Y416, and the addition of PP2 does not prevent the serine 17 phosphorylation but does block the Y416 phosphorylation. 43 We now show that c-Src activity is increased by fenoldopam and that blocking c-Src with PP2 prevents the AT 1 R downregulation. We speculate that the D 5 R is responsible for the activation of c-Src, because AT 1 R downregulation by fenoldopam is still operational in D 1 R uncoupled cells. Our future studies will concentrate on the intermediate pathway connecting the D 5 R to c-Src activation.
In summary, we have demonstrated that, in RPTCs from human kidneys, there is a transregulatory pathway whereby the D 5 R receptor downregulates the AT 1 R. This represents a novel mechanism to explain the dynamic balance between the natriuretic dopaminergic and antinatriuretic angiotensin systems in the kidney. 
Perspectives
The human kidney is the primary organ responsible for orchestrating a balance between sodium reabsorption and excretion to maintain fluid and electrolyte balance and, ultimately, blood pressure. Two principal pathways have been identified that act to increase sodium reabsorption (the renin-angiotensin system mainly stimulated by angiotensin II via AT 1 R) or decrease sodium reabsorption (the dopaminergic system working through dopamine produced in the kidney). It has been of interest to determine which cell-surface receptors are responsible for transducing these counterbalancing signals to enable the development of targeted pharmaceuticals. In this article we have delineated how these 2 systems work to regulate each other. More importantly, we have identified a novel AT 1 R regulatory pathway that relies on the independent action of the D 5 R that is mechanistically distinct from the D 1 R.
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